Results of ARI‐0001 CART19 cell therapy in patients with relapsed/refractory CD19‐positive acute lymphoblastic leukemia with isolated extramedullary disease
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26519
Abstract: We evaluated outcomes of 18 patients with isolated extramedullary disease (iEMD) relapsed/refractory (R/R) B‐cell acute lymphoblastic leukemia (B‐ALL) treated with the CD19‐directed CAR T cells ARI‐0001 in two centers (adult and pediatric), including patients treated… read more here.
Keywords: relapsed refractory; isolated extramedullary; extramedullary disease; lymphoblastic leukemia ... See more keywords
The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001
Sign Up to like & getrecommendations! Published in 2022 at "Bone Marrow Transplantation"
DOI: 10.1038/s41409-021-01463-y
Abstract: In February 2021, the ‘Advanced Therapy Medicinal Product’ (ATMP) ARI-0001 (CART19-BE-01), developed at Hospital Clínic de Barcelona (Spain), received authorization from the Spanish Agency of Medicines and Medical Devices (AEMPS) under the ‘hospital exemption’ (HE)… read more here.
Keywords: advanced therapy; therapy medicinal; ari 0001; hospital exemption ... See more keywords
P09.05 Immunogenicity induced by the academic chimeric antigen receptor CAR19 (ARI-0001) in patients with CD19-positive relapsed/refractory B-cell malignancies recruited into the CART19-BE-01 clinical trial
Sign Up to like & getrecommendations! Published in 2020 at "Journal for ImmunoTherapy of Cancer"
DOI: 10.1136/jitc-2020-itoc7.105
Abstract: Background Chimeric Antigen Receptor (CAR)-T cells directed against CD19 have induced high rates of response in patients with relapsed/refractory (R/R) B-cell malignancies. Two CD19-targeting constructs have been approved by the FDA and EMA (Yescarta ®,… read more here.
Keywords: ari 0001; none; immunogenicity induced; cart ... See more keywords